Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus

doi: 10.1128/AAC.02556-17

Figure Lengend Snippet: Antibacterial activities of DS-2969b and linezolid against aerobic bacteria

Article Snippet: DS-2969b and LZD showed time-dependent slow killing with exposures at 1×, 4×, and 16× MIC. table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Strain MIC (μg/ml) DS-2969b Linezolid Staphylococcus aureus ATCC 6538P 0.25 2 Staphylococcus epidermidis ATCC 14990 0.5 1 Streptococcus pneumoniae ATCC 49619 0.25 1 Streptococcus pyogenes ATCC 12344 ≤0.125 1 Enterococcus faecalis ATCC 29212 0.25 2 Enterococcus faecium ATCC 19434 2 4 Moraxella catarrhalis ATCC 25238 0.25 8 Haemophilus influenzae ATCC 49247 0.5 8 Klebsiella pneumoniae ATCC 13883 64 >128 Enterobacter cloacae ATCC 13047 >128 >128 Serratia marcescens ATCC 13880 32 >128 Proteus vulgaris ATCC 13315 16 16 Pseudomonas aeruginosa ATCC 15692 128 >128 Stenotrophomonas maltophilia ATCC 13637 64 >128 Acinetobacter baumannii ATCC 19606 64 >128 Open in a separate window Antibacterial activities of DS-2969b and linezolid against aerobic bacteria table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Compound MIC (μg/ml) Range 50% 90% DS-2969b 0.03–0.5 0.125 0.25 Linezolid 0.5–2 1 2 Vancomycin 0.03–2 1 2 Levofloxacin 8–32 32 32 Open in a separate window a A total of 67 isolates were tested.

Techniques: